Novocure to Report First Quarter 2023 Financial Results

Rhea-AI Summary

Novocure (NASDAQ: NVCR) will announce its first quarter 2023 financial results on May 4, 2023, before U.S. market opening. A conference call is scheduled for 8:00 a.m. ET the same day to discuss the results for the three months ending March 31, 2023. Investors can access the call via a registration link. Novocure focuses on innovative therapies for aggressive cancers and has multiple ongoing clinical studies.

Positive

• Scheduled financial results release for Q1 2023 on May 4, 2023.
• Ongoing clinical studies for Tumor Treating Fields in various cancers.

Negative

• None.

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2023, at 8:00 a.m. ET on Thursday, May 4, 2023. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2023, and subsequent flings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005046/en/

Investors:

Ingrid Goldberg

investorinfo@novocure.com

610-723-7427

Media:

Leigh Labrie

media@novocure.com

610-723-7428

Source: Novocure

FAQ

When will Novocure report its Q1 2023 earnings?

Novocure will report its Q1 2023 earnings on May 4, 2023.

What time is the Novocure Q1 2023 earnings call?

The Novocure Q1 2023 earnings call is scheduled for 8:00 a.m. ET on May 4, 2023.

How can I access Novocure's Q1 2023 earnings conference call?

You can access the conference call via the registration link provided in the press release.

What is the focus of Novocure's clinical studies?

Novocure is focusing on Tumor Treating Fields for various cancers, including glioblastoma and ovarian cancer.